Activity and Predicted Nephrotoxicity of Synthetic Antibiotics Based on Polymyxin B

Journal of Medicinal Chemistry

Volumn 59, Issue 3, 2016, Pages 1068-1077

  Gallardo Godoy, Alejandra ^a   Muldoon, Craig ^a   Becker, Bernd ^a   Elliott, Alysha G ^a   Lash, Lawrence H ^b   Huang, Johnny X ^a   Butler, Mark S ^a   Pelingon, Ruby ^a   Kavanagh, Angela M ^a   Ramu, Soumya ^a   Phetsang, Wanida ^a   Blaskovich, Mark A T ^a   Cooper, Matthew A ^a  

^a UNIVERSITY OF QUEENSLAND   (Australia)

^b WAYNE STATE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMINO ACID; ANTIBIOTIC AGENT; COLISTIN; GENTAMICIN; POLYMYXIN; POLYMYXIN B; VANCOMYCIN; ANTIINFECTIVE AGENT;

ACINETOBACTER BAUMANNII; ANTIBACTERIAL ACTIVITY; ARTICLE; CONTROLLED STUDY; CYTOTOXICITY; ESCHERICHIA COLI; GRAM NEGATIVE BACTERIUM; HEPG2 CELL LINE; HUMAN; HUMAN CELL; IN VITRO STUDY; KIDNEY CELL; KLEBSIELLA PNEUMONIAE; MAMMAL CELL; MINIMUM INHIBITORY CONCENTRATION; NEPHROTOXICITY; NONHUMAN; PSEUDOMONAS AERUGINOSA; STAPHYLOCOCCUS AUREUS; STRUCTURE ACTIVITY RELATION; STRUCTURE ANALYSIS; STRUCTURE TOXICITY ANALYSIS; ANALOGS AND DERIVATIVES; ANTIBIOTIC RESISTANCE; CELL LINE; CELL SURVIVAL; CHEMISTRY; CONFORMATION; DOSE RESPONSE; DRUG EFFECTS; HEK293 CELL LINE; HEP-G2 CELL LINE; KIDNEY; MICROBIAL SENSITIVITY TEST; SYNTHESIS;

ANTI-BACTERIAL AGENTS; CELL LINE; CELL SURVIVAL; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG RESISTANCE, BACTERIAL; HEK293 CELLS; HEP G2 CELLS; HUMANS; KIDNEY; KLEBSIELLA PNEUMONIAE; MICROBIAL SENSITIVITY TESTS; MOLECULAR CONFORMATION; POLYMYXIN B; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 84958167925     PISSN: 00222623     EISSN: 15204804     Source Type: Journal    
DOI: 10.1021/acs.jmedchem.5b01593     Document Type: Article

References (70)

1. Hall, M. J.; Williams, S. N.; DeFrances, C. J.; Golosinskiy, A. Inpatient care for septicemia or sepsis: a challenge for patients and hospitals NCHS Data Brief 2011, 1-8
2. Lagu, T.; Rothberg, M. B.; Shieh, M. S.; Pekow, P. S.; Steingrub, J. S.; Lindenauer, P. K. Hospitalizations, costs, and outcomes of severe sepsis in the United States 2003 to 2007 Crit. Care Med. 2012, 40, 754-761 10.1097/CCM.0b013e318232db65
3. Vincent, J. L.; Marshall, J. C.; Namendys-Silva, S. A.; Francois, B.; Martin-Loeches, I.; Lipman, J.; Reinhart, K.; Antonelli, M.; Pickkers, P.; Njimi, H.; Jimenez, E.; Sakr, Y.; investigators, I. Assessment of the worldwide burden of critical illness: the intensive care over nations (ICON) audit Lancet Respir. Med. 2014, 2, 380-6 10.1016/S2213-2600(14)70061-X
4. Torio, C. M.; Andrews, R. M. National Inpatient Hospital Costs: The Most Expensive Conditions by Payer, 2011: Statistical Brief #160. In Healthcare Cost and Utilization Project (HCUP) Statistical Briefs, Rockville, MD, 2011.
5. Opal, S. M.; Garber, G. E.; LaRosa, S. P.; Maki, D. G.; Freebairn, R. C.; Kinasewitz, G. T.; Dhainaut, J. F.; Yan, S. B.; Williams, M. D.; Graham, D. E.; Nelson, D. R.; Levy, H.; Bernard, G. R. Systemic host responses in severe sepsis analyzed by causative microorganism and treatment effects of drotrecogin alfa (activated) Clin. Infect. Dis. 2003, 37, 50-58 10.1086/375593
6. Butler, M. S.; Blaskovich, M. A.; Cooper, M. A. Antibiotics in the clinical pipeline in 2013 J. Antibiot. 2013, 66, 571-591 10.1038/ja.2013.86
7. Benedict, R. G.; Langlykke, A. F. Antibiotic activity of Bacillus polymyxa J. Bacteriol. 1947, 54, 24
8. Stansly, P. G.; Schlosser, M. E. Studies on polymyxin: Isolation and identification of Bacillus polymyxa and differentiation of polymyxin from certain known antibiotics J. Bacteriol. 1947, 54, 549-556
9. Stansly, P. G.; Shepherd, R. G.; White, H. J. Polymyxin: a new chemotherapeutic agent Bull. Johns Hopkins Hosp. 1947, 81, 43-54
10. Ainsworth, G. C.; Brown, A. M.; Brownlee, G. Aerosporin, an antibiotic produced by Bacillus aerosporus Greer Nature 1947, 159, 263 10.1038/160263a0
11. Shoji, J.; Hinoo, H.; Wakisaka, Y.; Koizumi, K.; Mayama, M.; Matsuura, S. Isolation of two new polymyxin group antibiotics. Studies on antibiotics from the genus Bacillus. XX J. Antibiot. 1977, 30, 1029-1034 10.7164/antibiotics.30.1029
12. Shoji, J.; Kato, T.; Hinoo, H. The structure of polymyxin S. Studies on antibiotics from the genus Bacillus. XXI J. Antibiot. 1977, 30, 1035-1041 10.7164/antibiotics.30.1035
13. Wilkinson, S.; Lowe, L. A. Structures of the polymyxins A and the question of identity with the polymyxins M Nature 1966, 212, 311 10.1038/212311a0
14. Parker, W. L.; Rathnum, M. L.; Dean, L. D.; Nimeck, M. W.; Brown, W. E.; Meyers, E. Polymyxin F, a new peptide antibiotic J. Antibiot. 1977, 30, 767-769 10.7164/antibiotics.30.767
15. Shoji, J.; Kato, T.; Hinoo, H. The structure of polymyxin T1. Studies on antibiotics from the genus Bacillus. XXII J. Antibiot. 1977, 30, 1042-1048 10.7164/antibiotics.30.1042
16. Stansly, P. G. The polymyxins; a review and assessment Am. J. Med. 1949, 7, 807-818 10.1016/0002-9343(49)90419-2
17. Velkov, T.; Roberts, K. D.; Nation, R. L.; Thompson, P. E.; Li, J. Pharmacology of polymyxins: new insights into an 'old' class of antibiotics Future Microbiol. 2013, 8, 711-724 10.2217/fmb.13.39
18. Kadar, B.; Kocsis, B.; Nagy, K.; Szabo, D. The renaissance of polymyxins Curr. Med. Chem. 2013, 20, 3759-3773 10.2174/09298673113209990185
19. Nation, R. L.; Velkov, T.; Li, J. Colistin and polymyxin B: peas in a pod, or chalk and cheese? Clin. Infect. Dis. 2014, 59, 88-94 10.1093/cid/ciu213
20. Kassamali, Z.; Rotschafer, J. C.; Jones, R. N.; Prince, R. A.; Danziger, L. H. Polymyxins: wisdom does not always come with age Clin. Infect. Dis. 2013, 57, 877-883 10.1093/cid/cit367
21. Nation, R. L.; Li, J. Colistin in the 21st century Curr. Opin. Infect. Dis. 2009, 22, 535-543 10.1097/QCO.0b013e328332e672
22. Biswas, S.; Brunel, J. M.; Dubus, J. C.; Reynaud-Gaubert, M.; Rolain, J. M. Colistin: an update on the antibiotic of the 21st century Expert Rev. Anti-Infect. Ther. 2012, 10, 917-934 10.1586/eri.12.78
23. Spapen, H.; Jacobs, R.; Van Gorp, V.; Troubleyn, J.; Honore, P. M. Renal and neurological side effects of colistin in critically ill patients Ann. Intensive Care 2011, 1, 14 10.1186/2110-5820-1-14
24. Carlos, C. P.; Mendes, G. E.; Miquelin, A. R.; Luz, M. A.; da Silva, C. G.; van Rooijen, N.; Coimbra, T. M.; Burdmann, E. A. Macrophage depletion attenuates chronic cyclosporine A nephrotoxicity Transplantation 2010, 89, 1362-1370 10.1097/TP.0b013e3181da0587
25. Sorli, L.; Luque, S.; Grau, S.; Berenguer, N.; Segura, C.; Montero, M. M.; Alvarez-Lerma, F.; Knobel, H.; Benito, N.; Horcajada, J. P. Trough colistin plasma level is an independent risk factor for nephrotoxicity: a prospective observational cohort study BMC Infect. Dis. 2013, 13, 380 10.1186/1471-2334-13-380
26. Nation, R. L.; Li, J.; Cars, O.; Couet, W.; Dudley, M. N.; Kaye, K. S.; Mouton, J. W.; Paterson, D. L.; Tam, V. H.; Theuretzbacher, U.; Tsuji, B. T.; Turnidge, J. D. Framework for optimization of the clinical use of colistin and polymyxin B: the Prato polymyxin consensus Lancet Infect. Dis. 2015, 15, 225-234 10.1016/S1473-3099(14)70850-3
27. Brink, A. J.; Richards, G. A.; Colombo, G.; Bortolotti, F.; Colombo, P.; Jehl, F. Multicomponent antibiotic substances produced by fermentation: implications for regulatory authorities, critically ill patients and generics Int. J. Antimicrob. Agents 2014, 43, 1-6 10.1016/j.ijantimicag.2013.06.013
28. Pristovsek, P.; Kidric, J. Solution structure of polymyxins B and E and effect of binding to lipopolysaccharide: an NMR and molecular modeling study J. Med. Chem. 1999, 42, 4604-4613 10.1021/jm991031b
29. Newton, B. A. The properties and mode of action of the polymyxins Bacteriol. Rev. 1956, 20, 14-27
30. Velkov, T.; Thompson, P. E.; Nation, R. L.; Li, J. Structure-activity relationships of polymyxin antibiotics J. Med. Chem. 2010, 53, 1898-1916 10.1021/jm900999h
31. Hancock, R. E.; Chapple, D. S. Peptide antibiotics Antimicrob. Agents Chemother. 1999, 43, 1317-1323
32. Sampson, T. R.; Liu, X.; Schroeder, M. R.; Kraft, C. S.; Burd, E. M.; Weiss, D. S. Rapid killing of Acinetobacter baumannii by polymyxins is mediated by a hydroxyl radical death pathway Antimicrob. Agents Chemother. 2012, 56, 5642-5649 10.1128/AAC.00756-12
33. Deris, Z. Z.; Akter, J.; Sivanesan, S.; Roberts, K. D.; Thompson, P. E.; Nation, R. L.; Li, J.; Velkov, T. A secondary mode of action of polymyxins against Gram-negative bacteria involves the inhibition of NADH-quinone oxidoreductase activity J. Antibiot. 2014, 67, 147-151 10.1038/ja.2013.111
34. Mogi, T.; Murase, Y.; Mori, M.; Shiomi, K.; Omura, S.; Paranagama, M. P.; Kita, K. Polymyxin B identified as an inhibitor of alternative NADH dehydrogenase and malate: quinone oxidoreductase from the Gram-positive bacterium Mycobacterium smegmatis J. Biochem. 2009, 146, 491-499 10.1093/jb/mvp096
35. Beceiro, A.; Llobet, E.; Aranda, J.; Bengoechea, J. A.; Doumith, M.; Hornsey, M.; Dhanji, H.; Chart, H.; Bou, G.; Livermore, D. M.; Woodford, N. Phosphoethanolamine modification of lipid A in colistin-resistant variants of Acinetobacter baumannii mediated by the pmrAB two-component regulatory system Antimicrob. Agents Chemother. 2011, 55, 3370-3379 10.1128/AAC.00079-11
36. Wright, M. S.; Suzuki, Y.; Jones, M. B.; Marshall, S. H.; Rudin, S. D.; van Duin, D.; Kaye, K.; Jacobs, M. R.; Bonomo, R. A.; Adams, M. D. Genomic and transcriptomic analyses of colistin-resistant clinical isolates of Klebsiella pneumoniae reveal multiple pathways of resistance Antimicrob. Agents Chemother. 2015, 59, 536-543 10.1128/AAC.04037-14
37. Magee, T. V.; Brown, M. F.; Starr, J. T.; Ackley, D. C.; Abramite, J. A.; Aubrecht, J.; Butler, A.; Crandon, J. L.; Dib-Hajj, F.; Flanagan, M. E.; Granskog, K.; Hardink, J. R.; Huband, M. D.; Irvine, R.; Kuhn, M.; Leach, K. L.; Li, B.; Lin, J.; Luke, D. R.; MacVane, S. H.; Miller, A. A.; McCurdy, S.; McKim, J. M., Jr.; Nicolau, D. P.; Nguyen, T. T.; Noe, M. C.; O'Donnell, J. P.; Seibel, S. B.; Shen, Y.; Stepan, A. F.; Tomaras, A. P.; Wilga, P. C.; Zhang, L.; Xu, J.; Chen, J. M. Discovery of Dap-3 polymyxin analogues for the treatment of multidrug-resistant Gram-negative nosocomial infections J. Med. Chem. 2013, 56, 5079-5093 10.1021/jm400416u
38. Magee, T. V.; Chen, J. M.; Martinez, C. A.; Li, Z. B. Polymyxin Derivates Useful As Antibacterial Agents. US20120316105, 2012.
39. Chen, J. M.; Magee, T. V.; Martinez, C. A. Polymyxin derivatives useful as antibacterial agents. WO/2012/168820, 2012.
40. Saadi, M.; Duperchy, E.; Brown, P.; Dawson, M. J.; Wadman, S. N. Polymyxin derivatives. WO/2013/072695, 2013.
41. Saadi, M.; Duperchy, E.; Brown, P.; Dawson, M. J.; Wadman, S. N. Compounds. US20150031602, 2015.
42. Brown, P.; Dawson, M.; Simonovic, M.; Boakes, S.; Duperchy, E. Polymyxin derivatives and their use in combination therapy together with different antibiotics. WO/2014/188178, 2014.
43. Vaara, M.; Fox, J.; Loidl, G.; Siikanen, O.; Apajalahti, J.; Hansen, F.; Frimodt-Moller, N.; Nagai, J.; Takano, M.; Vaara, T. Novel polymyxin derivatives carrying only three positive charges are effective antibacterial agents Antimicrob. Agents Chemother. 2008, 52, 3229-3236 10.1128/AAC.00405-08
44. Vaara, M. S.; Vaara, T. I. Polymyxin derivatives and uses thereof. US8329645, 2012.
45. Vaara, M. S.; Vaara, T. I. Polymyxin derivatives and uses thereof. US20140134669, 2014.
46. Sakura, N.; Itoh, T.; Uchida, Y.; Ohki, K.; Okimura, K.; Chiba, K.; Sato, Y.; Sawanishi, H. The contribution of the N-terminal structure of polymyxin B peptides to antimicrobial and lipopolysaccharide binding activity Bull. Chem. Soc. Jpn. 2004, 77, 1915-1924 10.1246/bcsj.77.1915
47. O'Dowd, H.; Kim, B.; Margolis, P.; Wang, W.; Wu, C.; Lopez, S. L.; Blais, J. Preparation of tetra-Boc-protected polymyxin B nonapeptide Tetrahedron Lett. 2007, 48, 2003-2005 10.1016/j.tetlet.2007.01.071
48. Weinstein, J.; Afonso, A.; Moss, E., Jr.; Miller, G. H. Selective chemical modifications of polymyxin B Bioorg. Med. Chem. Lett. 1998, 8, 3391-3396 10.1016/S0960-894X(98)00612-X
49. Leese, R. A.; Francis, N.; Curran, W.; Borders, D. B.; Jarolmen, H. Peptide Antibiotics amd Methods for Making Same. WO/2006/083317, 2006.
50. Curran, W. V.; Liu, C. M.; Bombardier, A. C. D.; Leese, R. A.; Hwang, Y. S.; Lippa, B. S.; Zhang, Y. Antibiotic compositions for the treatment of gram negative infections. US8415307, 2013.
51. Curran, W. V.; Liu, C. M.; Bombardier, A. C. D.; Leese, R. A.; Hwang, Y. S.; Lippa, B. S.; Zhang, Y. Antibiotic compositions for the treatment of gram negative infections. US20140073559, 2014.
52. Curran, W. V.; Liu, C. M.; Bombardier, A. C. D.; Leese, R. A.; Hwang, Y. S.; Lippa, B. S.; Zhang, Y. Antibiotic compositions for the treatment of gram negative infections. US8906866, 2014.
53. Leese, R. A.; Francis, N.; Curran, W. V.; Borders, D. B.; Jarolmen, H. Peptide antibiotics and methods for making same. US8889826B2, 2014.
54. Leese, R. A. Antibiotic compositions for the treatment of gram negative infections. US 8343912B2, 2013.
55. Quale, J.; Shah, N.; Kelly, P.; Babu, E.; Backer, M.; Rosas-Garcia, G.; Salamera, J.; George, A.; Bratu, S.; Landman, D. Activity of polymyxin B and the novel polymyxin analogue CB-182,804 against cntemporary gram-negative pathogens in New York City Microb. Drug Resist. 2012, 18, 132-136 10.1089/mdr.2011.0163
56. Velkov, T.; Roberts, K. D.; Nation, R. L.; Wang, J.; Thompson, P. E.; Li, J. Teaching 'old' polymyxins new tricks: new-generation lipopeptides targeting gram-negative 'superbugs' ACS Chem. Biol. 2014, 9, 1172-1177 10.1021/cb500080r
57. Li, J.; Velkov, T.; Nation, R. L; Thompson, P. E. Antimicrobial compounds. WO/2010/130007, 2010.
58. Li, J.; Velkov, T.; Nation, R. L.; Thompson, P. E.; Roberts, K. D. Antimicrobial compounds. WO/2012/051663, 2012.
59. Storm, D. R.; Rosenthal, K. S.; Swanson, P. E. Polymyxin and related peptide antibiotics Annu. Rev. Biochem. 1977, 46, 723-763 10.1146/annurev.bi.46.070177.003451
60. Vaara, M. Novel derivatives of polymyxins J. Antimicrob. Chemother. 2013, 68, 1213-1219 10.1093/jac/dkt039
61. Mingeot-Leclercq, M. P.; Tulkens, P. M.; Denamur, S.; Vaara, T.; Vaara, M. Novel polymyxin derivatives are less cytotoxic than polymyxin B to renal proximal tubular cells Peptides 2012, 35, 248-252 10.1016/j.peptides.2012.03.033
62. Sharma, S. K.; Wu, A. D.; Chandramouli, N.; Fotsch, C.; Kardash, G.; Bair, K. W. Solid-phase total synthesis of polymyxin B1 J. Pept. Res. 1999, 53, 501-506 10.1034/j.1399-3011.1999.00045.x
63. Huang, J. X.; Blaskovich, M. A.; Cooper, M. A. Cell- and biomarker-based assays for predicting nephrotoxicity Expert Opin. Drug Metab. Toxicol. 2014, 10, 1621-1635 10.1517/17425255.2014.967681
64. Huang, J. X.; Kaeslin, G.; Ranall, M. V.; Blaskovich, M. A.; Becker, B.; Butler, M. S.; Little, M. H.; Lash, L. H.; Cooper, M. A. Evaluation of biomarkers for in vitro prediction of drug-induced nephrotoxicity: comparison of HK-2, immortalized human proximal tubule epithelial, and primary cultures of human proximal tubular cells Pharmacol. Res. Perspect. 2015, 3, e00148 10.1002/prp2.148
65. Lash, L. H.; Putt, D. A.; Zalups, R. K. Biochemical and functional characteristics of cultured renal epithelial cells from uninephrectomized rats: factors influencing nephrotoxicity J. Pharmacol. Exp. Ther. 2001, 296, 243-251
66. Gottlieb, H. E.; Kotlyar, V.; Nudelman, A. NMR chemical shifts of common laboratory solvents as trace impurities J. Org. Chem. 1997, 62, 7512-7515 10.1021/jo971176v
67. McMillian, M. K.; Li, L.; Parker, J. B.; Patel, L.; Zhong, Z.; Gunnett, J. W.; Powers, W. J.; Johnson, M. D. An improved resazurin-based cytotoxicity assay for hepatic cells Cell Biol. Toxicol. 2002, 18, 157-173 10.1023/A:1015559603643
68. O'Brien, J.; Wilson, I.; Orton, T.; Pognan, F. Investigation of the Alamar Blue (resazurin) fluorescent dye for the assessment of mammalian cell cytotoxicity Eur. J. Biochem. 2000, 267, 5421-5426 10.1046/j.1432-1327.2000.01606.x
69. Cummings, B. S.; Lash, L. H. Metabolism and toxicity of trichloroethylene and S-(1,2-dichlorovinyl)- l -cysteine in freshly isolated human proximal tubular cells Toxicol. Sci. 2000, 53, 458-66 10.1093/toxsci/53.2.458
70. Lash, L. H.; Putt, D. A.; Cai, H. Drug metabolism enzyme expression and activity in primary cultures of human proximal tubular cells Toxicology 2008, 244, 56-65 10.1016/j.tox.2007.10.022